オプションチェーンは、Afyaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Afyaの市場センチメントを評価します。.

Afya (NASDAQ:AFYA) 株価情報, オプションチェーン

Afya

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.

Afya Ltd

Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) on Thursday reported better-than-expected fourth-quarter results but lowered its forward guidance for the next quarter. Analysts <a href="https://www.benzinga.com/news/earnings/25/01/43354712/intel-stock-climbs-on-better-than-expected-q4-report-details">weighed in on the report.&nbsp;</a>
Expert Ideas: Cantor Fitzgerald analyst C.J. Muse highlighted Intel's better-than-feared fourth quarter driven by the Intel Products side with Foundry results coming in as expected.&nbsp;
The analyst also noted Intel lowered its capital expenditures guidance which he said was the "right step" in order for the company to return to positive free cash flow in 2025. Muse maintained a Neutral rating and $22 price target on Intel stock.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/earnings/25/01/43400701/ups-ceo-says-amazon-is-our-largest-but-not-our-most-profitable-customer">UPS CEO Says Amazon Is &#8216;Our Largest,&#8217; But &#8216;Not Our Most Profitable Customer&#8217;&nbsp;</a>
Oppenheimer analysts noted all product segments guided down by approximately 14% for the first quarter and that Intel continues to lose market share to Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) in both its Client Computing Group and Data Center segments. 
Oppenheimer said it "remains on the sidelines as turnaround efforts take root" and maintained a Perform rating on Intel shares.&nbsp;
Stifel analysts also pointed to the company's reduced guidance and slow recovery and remain on the sidelines "until execution starts yielding results." Stifel maintained its Hold rating on Intel but lowered its price target from $25 to $21.&nbsp;
Several other analysts <a href="https://www.benzinga.com/quote/INTC/analyst-ratings">updated coverage</a> on Intel following the fourth-quarter print:&nbsp;
<ul>
<li>JPMorgan analyst Harlan Sur maintained Intel with an Underweight and lowered the price target from $26 to $23.</li>
<li>Wells Fargo analyst Aaron Rakers maintained an Equal-Weight rating but lowered the price target on Intel from $28 to $25.</li>
<li>Benchmark analyst Cody Acree reiterated Intel with a Hold rating.&nbsp;</li>
<li>Needham analyst Quinn Bolton reiterated a Hold rating.&nbsp;</li>
</ul>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43320124/microsoft-shares-slide-after-q2-results-cloud-revenue-misses-expectations-details">Microsoft Shares Slide After Q2 Results, Cloud Revenue Misses Expectations: Details</a>&nbsp;</li>
</ul>
Photo: Shutterstock

Analyst Color

Earnings

News

Reiteration

Analyst Ratings

Movers

Tech

INTC

Intel Attempts Turnaround, Analysts 'Remain On The Sidelines'

8 analysts have expressed a variety of opinions on Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $2.77, a high estimate of $6.00, and a low estimate of $1.70. This current average represents a 16.31% decrease from the previous average price target of $3.31. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360869_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Angi. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$1.70</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.70</td>
<td>$2.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$3.25</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$3.00</td>
<td>$3.25</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$3.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Angi. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Angi compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Angi's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Angi's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ANGI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Angi analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Angi: A Closer Look</h2>
Angi Inc connects quality home service professionals across different categories, from repairing and remodeling to cleaning and landscaping, with consumers. The Company has three operating segments namely, Ads and Leads that generate maximum revenue, Services, and International (Europe and Canada). The company operates under multiple brands that including Angi, HomeAdvisor, and Handy. The majority of the revenue is earned from the United States.
<h3>Angi: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Angi's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -15.52%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Angi's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.85% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Angi's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.33%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Angi's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.9%, the company showcases efficient use of assets and strong financial health.
Debt Management: Angi's debt-to-equity ratio is below the industry average. With a ratio of 0.46, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANGI

The Analyst Verdict: Angi In The Eyes Of 8 Experts

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Carvana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $296.7, with a high estimate of $350.00 and a low estimate of $245.00. This upward trend is evident, with the current average reflecting a 11.33% increase from the previous average price target of $266.50.
<img src="https://www.benzinga.com/files/images/story/2025/1738360858_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Carvana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$277.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$280.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$330.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>David Lantz</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Chris Pierce</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$330.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Montani</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Carvana. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Carvana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Carvana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Carvana's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CVNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Carvana analyst ratings.</a>
<h2>Get to Know Carvana Better</h2>
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
<h3>Unraveling the Financial Story of Carvana</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Carvana displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 31.81%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Carvana's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 14.95% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: Carvana's debt-to-equity ratio stands notably higher than the industry average, reaching 10.06. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CVNA

Assessing Carvana: Insights From 10 Financial Analysts

11 analysts have shared their evaluations of IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for IAC, revealing an average target of $68.18, a high estimate of $110.00, and a low estimate of $14.00. This current average represents a 5.54% decrease from the previous average price target of $72.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360842_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of IAC by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Ygal Arounian</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$56.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Youssef Squali</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Kurnos</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IAC. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of IAC compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of IAC's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IAC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IAC analyst ratings.</a>
<h2>Discovering IAC: A Closer Look</h2>
IAC is an internet media company with segments that include Angi (33% of total revenue), Dotdash Meredith (39%), search (14%), and emerging and other (14%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
<h3>Financial Milestones: IAC's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: IAC's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -15.53%. This indicates a decrease in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -25.96%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): IAC's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -4.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): IAC's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: IAC's debt-to-equity ratio is below the industry average at 0.35, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 11 Analysts Discuss IAC Stock

In the latest quarter, 15 analysts provided ratings for Dow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $47.4, a high estimate of $60.00, and a low estimate of $38.00. A 10.92% drop is evident in the current average compared to the previous average price target of $53.21. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360833_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Dow by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$44.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Eric Boyes</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dow. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Dow compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Dow's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Dow's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dow analyst ratings.</a>
<h2>Discovering Dow: A Closer Look</h2>
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
<h3>Financial Milestones: Dow's Journey</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Dow displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 1.39%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Dow's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.94%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dow's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.15%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Dow's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.36%, the company showcases efficient use of assets and strong financial health.
Debt Management: Dow's debt-to-equity ratio surpasses industry norms, standing at 0.98. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Dow Through The Eyes Of 15 Analysts

In the last three months, 11 analysts have published ratings on Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $35.18, along with a high estimate of $40.00 and a low estimate of $30.00. Marking an increase of 7.49%, the current average surpasses the previous average price target of $32.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360824_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Confluent by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Howard Ma</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$31.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Confluent. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Confluent compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Confluent's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Confluent's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CFLT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Confluent analyst ratings.</a>
<h2>Delving into Confluent's Background</h2>
Confluent Inc is a new category of data infrastructure designed to connect all the applications, systems, and data layers of a company around a real-time central nervous system. Its products include Confluent Platform; Connectors; ksqlDB and others. The company generates revenue from the sale of subscriptions and services. Geographically, it derives a majority of its revenue from the United States. The company provides solutions to Financial Services; Insurance; Retail and eCommerce; Automotive; Government and other sectors.
<h3>Understanding the Numbers: Confluent's Finances</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Confluent's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 24.99%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -29.63%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Confluent's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.2%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Confluent's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.89%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Confluent's debt-to-equity ratio surpasses industry norms, standing at 1.19. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CFLT

Assessing Confluent: Insights From 11 Financial Analysts

In the last three months, 5 analysts have published ratings on Cullen/Frost Bankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFR#NYSE">CFR</a>), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $132.8, a high estimate of $145.00, and a low estimate of $113.00. Observing a 10.48% increase, the current average has risen from the previous average price target of $120.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1738360815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Cullen/Frost Bankers among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$144.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Brady Gailey</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$140.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$122.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Ben Gerlinger</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Sell</td>
<td>$113.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cullen/Frost Bankers. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Cullen/Frost Bankers compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cullen/Frost Bankers's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Cullen/Frost Bankers's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CFR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cullen/Frost Bankers analyst ratings.</a>
<h2>Unveiling the Story Behind Cullen/Frost Bankers</h2>
Cullen/Frost is a regional us bank with around $50 billion in assets (as of 2023 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
<h3>Unraveling the Financial Story of Cullen/Frost Bankers</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Cullen/Frost Bankers's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 5.42%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 27.65%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.81%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Cullen/Frost Bankers's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Cullen/Frost Bankers: What You Need To Know

Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) has outperformed the market over the past 20 years by 1.29% on an annualized basis producing an average annual return of 9.67%. Currently, Marvell Tech has a market capitalization of $97.66 billion. 
Buying $1000 In MRVL: If an investor had bought $1000 of MRVL stock 20 years ago, it would be worth $6,519.93 today based on a price of $112.86 for MRVL at the time of writing.
<h3>Marvell Tech's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738360811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MRVL

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today

Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) has outperformed the market over the past 5 years by 9.0% on an annualized basis producing an average annual return of 21.84%. Currently, Raymond James Finl has a market capitalization of $34.47 billion. 
Buying $100 In RJF: If an investor had bought $100 of RJF stock 5 years ago, it would be worth $274.82 today based on a price of $168.48 for RJF at the time of writing.
<h3>Raymond James Finl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738359909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Raymond James Finl Stock In The Last 5 Years

SR Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRBK#NASDAQ">SRBK</a>) reported quarterly earnings of $0.12 per share. This is a 33.33 percent decrease over earnings of $0.18 per share from the same period last year.

SRBK

SR Bancorp Q4 EPS $0.12 Down From $0.18 YoY

It took only four sessions for the U.S. stock market to recover most of the losses triggered earlier in the week after the Chinese startup DeepSeek launched a more efficient and cost-effective AI platform than OpenAI&#8216;sChatGPT, sparking a sharp <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43239042/magnificent-seven-broadcom-lose-nearly-900-billion-in-value-as-deepseek-sparks-ai-carnage-why-this-expert-is-still-bullish-on-us-tech">selloff on Wall Street.</a>
Investors began questioning the need to allocate capital to higher-cost AI-related companies, sending shares of top chipmakers and data <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43267966/deepseeks-low-cost-model-reshapes-ai-landscape-experts-predict-shift-to-application-layer">centers into a tailspin.</a>
Yet resilient quarterly earnings reports and a significantly less hawkish Federal Reserve Chair Jerome Powell compared to his stance in December gave bulls the confidence to buy the dip.
As widely expected, the Federal Reserve left interest rates <a href="https://www.benzinga.com/25/01/43316048/fed-holds-interest-rates-steady-halts-streak-of-consecutive-cuts-as-inflation-remains-elevated">unchanged at 4.25%–4.5%.</a> Surprisingly, Powell instilled greater hopes for potential rate cuts in the future, stating that monetary <a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43318325/a-different-powell-emerges-fed-chair-softens-hawkish-tone-on-interest-rates-bitcoin">policy remains "meaningfully restrictive."</a>
The scars remained visible for Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which lost about 15% in a week, with the chipmaker falling again on Friday following reports that U.S. plans to levy a 10% tariff on China.
Risk sentiment deteriorated during Friday afternoon trading in New York amid escalating tariff concerns.
President Donald Trump said again he plans to introduce 25% tariffs on imports from Mexico and Canada, though reports differed on when it would go into effect. 
On Friday, White House press secretary Karoline Leavitt said tariffs are coming Saturday.
&#8220;The President will implement 25% [tariffs] on Mexico, Canada and 10% on China,&#8221; Leavitt stated. 
Analysts warn that such a measure could cause significant economic disruptions in North America, with the U.S. automotive industry<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43398182/trumps-25-tariffs-could-slaughter-canada-mexico-economies-hit-us-auto-industry-analysts-warn"> among the most affected.</a>
Cruise liners were among the best performers in the S&amp;P 500 for the week, with Royal Caribbean Cruise Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) all posting double-digit percentage gains following strong <a href="https://www.benzinga.com/general/travel/25/01/43312480/royal-caribbean-cruises-posts-q4-beat-a-compelling-long-term-strategy-says-analyst">earnings from Royal Caribbean.</a>
United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) was one of the worst laggards, plunging about 15% — its worst week since September 2008 — after the parcel service agreed with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) to phase out more than 50% of the e-commerce giant&#8217;s volume by <a href="https://www.benzinga.com/25/01/43389661/these-analysts-cut-their-forecasts-on-ups-following-q4-earnings">the second half of 2026.</a>
You might have missed…
<h3 class="wp-block-heading">Microsoft AI Strength</h3>
Wall Street analysts assessed Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>)'s quarterly results, weighing Azure's slowing growth against its AI-driven potential. Despite cloud challenges, analysts said Microsoft remains a compelling investment due to its strategic <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/43351098/microsoft-analysts-weigh-azure-weakness-against-ai-strength-most-compelling-investment-opportunities">advancements in artificial intelligence.</a>
<h3 class="wp-block-heading">Musk Wins Back Advertisers</h3>
Amazon.com is increasing its ad spending on X, reversing previous cuts. Apple Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NYSE">AAPL</a>) is also considering resuming ads on the platform, signaling a potential recovery in advertiser confidence <a href="https://www.benzinga.com/general/social-media/25/01/43373012/elon-musk-bringing-advertisers-back-to-x-amazon-boosts-spending-apple-considers-return">under Elon Musk's leadership.</a>
<h3 class="wp-block-heading">GM Earnings Beat</h3>
General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) exceeded earnings expectations last quarter, posting strong revenue growth. Yet the company incurred over $5 billion in charges after halting funding for its Cruise robotaxi business and <a href="https://www.benzinga.com/25/01/43263700/general-motors-stock-gains-after-q4-earnings-beat-incurs-charges-from-funding-halt-of-cruise-robotaxi-business">restructuring operations in China</a>. Analysts remain optimistic about GM&#8217;s long-term <a href="https://www.benzinga.com/25/01/43315953/general-motors-turnaround-on-track-despite-ev-roadblocks-analysts-view">growth and turnaround potential.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43354861/vanguards-voo-set-to-overtake-spy-as-worlds-largest-etf-after-record-january-inflows">Vanguard&#8217;s VOO Set To Overtake SPY As World&#8217;s Largest ETF After Record January Inflows</a></li>
</ul>

Equities

Government

Large Cap

Regulations

Econ #s

Federal Reserve

Markets

AAPL

AMZN

MSFT

NCLH

NVDA

Stocks Trim DeepSeek Losses, Fed Holds Steady, Trump Slaps 25% Tariffs On Canada, Mexico: This Week In The Markets

The earnings results for Territorial Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBNK#NASDAQ">TBNK</a>) for Q4 were made public on Friday, January 31, 2025 at 04:30 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Territorial Bancorp missed estimated earnings by -150.0%, reporting an EPS of $-0.2 versus an estimate of $-0.08.
Revenue was up $7.94 billion from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company missed on EPS by $0.1 in the previous quarter, leading to a 2.0% increase share price change the next day.
Here's a look at Territorial Bancorp's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>-0.03</td>
<td>0.02</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.15</td>
<td>-0.09</td>
<td>-0.06</td>
<td>0.04</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>8.10M</td>
<td>9.03M</td>
<td>9.88M</td>
<td>10.25M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>8.10M</td>
<td>8.90M</td>
<td>9.35M</td>
<td>10.02M</td>
</tr>
</tbody>
</table>

 Listen to the earnings announcement yourself by <a href="">clicking here</a>. 
To track all earnings releases for Territorial Bancorp <a href="https://www.benzinga.com/quote/TBNK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TBNK

Earnings Breakdown: Territorial Bancorp Q4

Spirit AeroSystems Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPR#NYSE">SPR</a>) today announced that, at the special meeting of its shareholders held earlier today, its shareholders voted to approve the proposed acquisition of Spirit AeroSystems by The Boeing Company. The transaction, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4352793-1&amp;h=764042815&amp;u=https%3A%2F%2Fwww.spiritaero.com%2Fpages%2Frelease%2Fspirit-aerosystems-announces-acquisition-by-boeing-in-8.3-billion-transaction%2F&amp;a=announced+last+summer">announced last summer</a>, is expected to close in mid-2025, subject to closing conditions including the receipt of regulatory approvals.

Spirit AeroSystems Shareholders Approve Acquisition By Boeing; Expected To Close In Mid-2025

Territorial Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBNK#NASDAQ">TBNK</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.08) by 150 percent. This is a 600 percent decrease over earnings of $0.04 per share from the same period last year.

Earnings Misses

Territorial Bancorp Q4 EPS $(0.20) Misses $(0.08) Estimate

Affinity Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFBI#NASDAQ">AFBI</a>) reported quarterly earnings of $0.20 per share. This is a 13.04 percent decrease over earnings of $0.23 per share from the same period last year.

AFBI

Affinity Bancshares Q4 EPS $0.20 Down From $0.23 YoY

ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) has outperformed the market over the past 10 years by 18.63% on an annualized basis producing an average annual return of 29.94%. Currently, ServiceNow has a market capitalization of $210.00 billion. 
Buying $1000 In NOW: If an investor had bought $1000 of NOW stock 10 years ago, it would be worth $13,649.38 today based on a price of $1017.02 for NOW at the time of writing.
<h3>ServiceNow's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738359009_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

The U.S. Food and Drug Administration <a href="https://in.benzinga.com/trading-ideas/movers/25/01/43395856/vertex-pharmaceuticals-shares-are-up-today-whats-going-on">approved</a> the first new pain reliever to hit the market in over 20 years. This medication, produced by Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), is a non-opioid and therefore non-addictive. The new drug, suzetrigine, will be sold under the brand name Journavx.
Unlike opioids, Journavx blocks pain signals in the peripheral nervous system, not in the brain, so it does not create the same pleasurable effects usually felt with opioids and which often leads to dependence or addiction.
"A new non-opioid analgesic therapeutic class for acute pain offers an opportunity to mitigate certain risks associated with using an opioid for pain and provides patients with another treatment option," Dr. Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research, <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-novel-non-opioid-treatment-moderate-severe-acute-pain">said</a> in a press release. "This action and the agency's designations to expedite the drug's development and review underscore FDA's commitment to approving safe and effective alternatives to opioids for pain management."
Now Read: <a href="http://Purdue Pharma, Sackler Family To Pay $7.4 Billion In Settlement Over OxyContin That Fueled 'Devastating' Opioid Epidemic">Purdue Pharma, Sackler Family To Pay $7.4 Billion In Settlement Over OxyContin That Fueled &#8216;Devastating&#8217; Opioid Epidemic</a>
Government surveys show analgesics, or medications that control pain, are the most commonly prescribed type of drug in hospitals. And, <a href="https://www.cdc.gov/nchs/products/databriefs/db491.htm">according</a> to the Centers for Disease Control drug overdoses related to opioids, including Fentanyl are among the leading causes of accidental death in the U.S.  
Approximately 125 million opioid prescriptions were dispensed&nbsp;to American patients in 2023 to treat moderate to severe pain, <a href="https://www.cdc.gov/overdose-prevention/about/prescription-opioids.html#:~:text=Approximately%20125%20million%20opioid%20prescriptions,dose%20in%20the%20smallest%20quantity.">according</a> to the CDC. 
Meanwhile, <a href="https://www.benzinga.com/topic/medical-cannabis">medical marijuana</a> has been doing its part to help treat pain safely and effectively.
<h1 class="wp-block-heading">Large Study Provides New Insights: It&#8217;s About The Side-Effects</h1>
One of the <a href="https://www.benzinga.com/markets/cannabis/24/01/36578723/huge-study-reveals-cannabis-provides-similar-pain-relief-benefits-as-opioids-without-negative-co">largest studies to date</a>, which viewed 90 randomized controlled trials involving 22,028 participants, weighed the pain-alleviating potential of&nbsp;<a href="https://www.benzinga.com/cannabis" target="_blank" rel="noreferrer noopener">medical marijuana</a>&nbsp;versus opioids. The study was undertaken by the Canadian Institutes of Health Research&nbsp;and&nbsp;Health Canada. 
The <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10773353/" target="_blank" rel="noreferrer noopener">research</a> showed opioids and medical marijuana both offer moderate improvements in pain intensity for the treatment of non-cancer pain, which impacts 20% of people around the world and is generally treated with opioids.
The difference is in the side effects. Participants using medical marijuana were found to be far less likely to abandon treatment due to adverse effects as compared to those using opioids. That, in addition to the fact cannabis does not cause respiratory depression which can result from opioid consumption. Marijuana is also not considered to be physically addictive although <a href="https://drugabuse.com/blog/marijuana-addiction/">research contends</a> that regular as well as heavy consumers can develop a psychological dependence on marijuana depending on the individual.
Whereas with opioids, "Anyone taking prescription opioids is at risk for unintentional overdose or death and can become addicted regardless of race, gender, income level, or social class," <a href="https://www.cdc.gov/overdose-prevention/about/prescription-opioids.html#:~:text=Approximately%20125%20million%20opioid%20prescriptions,dose%20in%20the%20smallest%20quantity.">noted</a> the CDC.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43403416/is-big-pharma-about-to-win-goldman-sachs-weighs-in-on-340b-and-medicaid-shifts">Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts</a></li>
</ul>
Photo: Shutterstock

Cannabis

Health Care

VRTX

FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief

Pathfinder Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBHC#NASDAQ">PBHC</a>) reported quarterly earnings of $0.69 per share. This is a 68.29 percent increase over earnings of $0.41 per share from the same period last year.

PBHC

Pathfinder Bancorp Q4 EPS $0.69 Up From $0.41 YoY

The&nbsp;J.M. Smucker Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) announced today it has reached a definitive agreement to divest its Cloverhill and Big Texas&nbsp;brands, as well as certain private label products, to JTM Foods, LLC (JTM). The all-cash transaction is valued at approximately $40 million, subject to a working capital adjustment, and includes relevant trademarks and licenses and the Company's manufacturing facility in Chicago, Illinois. Approximately 400 employees will also transition with the business.

Contracts

Asset Sales

J.M. Smucker Announces $40M Divestment Of Cloverhill, Big Texas Brands To JTM Foods; 400 Employees To Transition With The Business

Fluor Corporation Announces That Its Mining & Metals Business Was Awarded A Joint Venture Contract With Hatch To Perform Engineering, Procurement And Construction Management) for BHP's Proposed Olympic Dam Smelter & Refinery Expansion Project in South Australia

Analyst Fred Mendes from Bank of America Securities maintained a Buy rating on Afya (AFYA – Research Report) and keeping the price target at $25.00...

Afya: Strong Financial Performance and Strategic Growth Justify Buy Rating

In a report released today, Mauricio Cepeda from Morgan Stanley maintained a Hold rating on Afya (AFYA – Research Report), with a price target of $...

Afya's Strong Growth Balanced by Acquisition Costs and Debt Concerns, Maintains Hold Rating

Afya Continues To Be An Opportunity Even After Brazil's Depreciation

Goldman Sachs initiated coverage of Afya (AFYA) with a Sell rating and $16 price target Afya is the largest medical education ecosystem in Brazil, ...

Afya initiated with a Sell at Goldman Sachs

07:18 EST Afya (AFYA) sinks 10% to $15.00 after Goldman starts with Sell rating Published first on TheFly – the ultimate source for real-time, mark...

Afya sinks 10% to $15.00 after Goldman starts with Sell rating

The latest update is out from Afya ( ($AFYA) ). Afya Limited announced the acquisition of Faculdade Única de Contagem through its subsidiary, addin...

Afya Limited Expands in Minas Gerais with Strategic Acquisition

Afya (AFYA) has entered into a share purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participacoes, of 100% of the...

Afya to acquire Faculdade Unica de Contagem for R$100M

White Brook Capital Partners Q4 2024 Commentary

Citi downgraded Afya (AFYA) to Sell from Neutral with a price target of $15, down from $18. The firm cites valuation grounds for the downgrade. Eve...

Afya downgraded to Sell from Neutral at Citi

Citi analyst Leandro Bastos downgraded Afya (AFYA – Research Report) to a Sell yesterday and set a price target of $15.00. The company's shares clo...

Citi downgrades Afya (AFYA) to a Sell

AFYA

BLDR

DNUT

GPRE

INFU

OKTA

PTLO

RPID

Press Releases

Afya Limited Releases 2023 Sustainability Report

Afya Secures Loan of up to R$500 Million From IFC to Support the Company's Expansion

Afya Limited Announces Second-Quarter and First-Half 2024 Financial Results

Afya Secures Full Disbursement of R$500 Million From IFC to Support the Company's Expansion

Afya Limited Announces MEC Decision on Medical Seats Reconsideration in Unigranrio

Afya Assumes a Voluntary Commitment to Free Health Consultations

Afya Limited to Host Afya Day 2024 on October 29th | Hybrid Event

Afya Limited to Report Third Quarter and Nine Months 2024 Financial Results on November 13th

Afya Limited Third Quarter and Nine Months 2024 Financial Results

Afya Limited Announces Entering Into a Share Purchase Agreement for the Acquisition of Faculdade Única de Contagem

American Public Education, Inc. - Common Stock

American Public Education

Adtalem Global Education Inc. Common Stock

Adtalem Glb Education

Bright Horizons Family Solutions Inc. Common Stock

Bright Horizons Family

Chegg

Coursera

Youdao, Inc. American Depositary Shares, each representing one Class A Ordinary Share

Youdao

Duolingo

New Oriental Education & Technology Group, Inc. Sponsored ADR representing 10 Ordinary Share (Cayman Islands)

Comments

Afya

Afya (AFYA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル